Donga St Co News Today : Breaking News, Live Updates & Top S

NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone

Published: May 22, 2024

NeuroBo Pharmaceuticals, Inc. , a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today announced that pre-clinical data suggests that DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist,...

Source: lelezard.com

NeuroBo Pharmaceuticals : Company Presentation May 2024

Published: May 21, 2024

NeuroBo Pharmaceuticals, Inc. May 2024 NASDAQ: NRBO ...

Source: marketscreener.com

NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June

Published: April 30, 2024

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases,...

Source: prnewswire.com

NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update

Published: March 28, 2024

Received First Site Institutional Review Board (IRB) Approval to Proceed With the Phase 1 Trial of DA-1726 in Obesity Phase 1 Trial of DA-1726 Expected to Dose...

Source: prnewswire.com

NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Published: March 13, 2024

Blinded Safety Review Completed for the First 6 Months of the Phase 2a Clinical Trial Conduct; Recommending Trial Continue Without Modification Full Data Readout Expected in the Second Half of...